[Combined sinus lift procedure and lateral augmentation. A treatment concept for the surgical and prosthodontic rehabilitation of the extremely atrophic maxilla].

Purpose: This paper describes a surgical and prosthetic procedure for treating the extremely atrophic maxilla. It explains a two-staged surgical technique, donor and recipient site morbidity, implant survival, and the implant-retained prosthetic rehabilitation of the patients.

Patients And Methods: A total of 57 consecutive patients were treated with a sinus lifting procedure and a simultaneous lateral augmentation using autogenous corticocancellous block and particulate bone grafts from the iliac crest.

[A new splint technique in dental traumatology].

The treatment of displacement injuries and fractures of permanent teeth is an important emergency therapy in the dental office. Due to new sport trends and various outdoor activities, the frequency of dental trauma of children and adolescents alike is steadily rising. The standard treatment of displacement or avulsion injuires of permanent teeth is repositioning or replantation with subsequent splinting.

Long-term stability of osseointegrated implants in augmented bone: a 5-year prospective study in partially edentulous patients.

This prospective clinical study evaluated the 5-year survival and success rates of 66 titanium implants placed in bone that had been previously augmented with autografts and nonresorbable barrier membranes. During the observation period, three patients with five implants dropped out of the study. None of the remaining 61 implants were lost during the follow-up period (implant survival rate of 100%).

[Health-related quality of life.].

Introduction: With increasing technology in medicine and possibilities to extend life, interest for studying health-related quality of life, i.e. the subjective well-being of patients against the background of their diseases, accidents or treatment, has increased.

Unemployment, coping and psychological distress.

This study addressed the role of coping style in anxiety and depression of unemployed people. Two-hundred thirty-three people checking in at unemployment services participated. They filled in Carver, Scheier and Weintraub's (1989) coping measure (COPE), the Hospital Anxiety and Depression scale (HAD), gave information as to age, duration of unemployment and their appraisal of their situation.

Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck.

Sera from 256 patients with cancers of the head and neck were examined for their profiles of IgG and IgA antibodies to Epstein-Barr virus (EBV)-specific, viral capsid antigen (VCA), the diffuse (D) and the restricted (R) components of the early antigen (EA) complex, and the EBV-associated nuclear antigen (EBNA), in order to assess the value of these procedures in the routine diagnosis of poorly or undifferentiated nasopharyngeal carcinoma (NPC). In 13 NPC patients, the carcinoma had invaded cervical lymph nodes, and their sera revealed, in addition to high IgG anti-VCA titers, elevated levels of IgA antibodies to VCA, of IgG antibodies to D, and most also had IgA anti-D. Such profiles were seen in very few of the patients with carcinomas at other sites of the head and neck.

Adjuvant interferon treatment of human osteosarcoma.

This paper updates the results of the clinical trial to examine the efficacy of exogenous leukocyte interferon therapy as adjuvant treatment for osteosarcoma. So far the incidence of metastases is lower and the survival rate is better for the interferon-treated group than for the concurrent control group. The number of treated patients is too small at present to allow proper statistical calculations to be made.

Immune reactions and long-term therapy with human leukocyte interferon.

Twenty patients with osteosarcoma were treated with exogenous human leukocyte interferon for periods ranging from 6 to 18 months. Eleven of them remained free from detectable tumour growth during this treatment. Blood samples from all patients were tested for antibodies against interferon and against impurities in the interferon preparations.

Virus infections and recurrence of osteosarcoma in patients receiving human leukocyte interferon.

Human leukocyte interferon was given as adjuvant treatment for osteosarcoma in 26 patients. Blood from these patients was studied at regular intervals for antibodies to various micro-organisms. A continuous record of clinically manifest infections during the course of interferon therapy was made in 23 of the 26 patients.

Correlation between prognostic factors and blood variables in osteosarcoma.

Prognostic factors and the blood chemistry were analyzed prior to treatment in 33 consecutive patients with primary osteosarcoma. The only variables of blood chemistry with values outside the normal range were alkaline phosphatase and ESR, which were increased. There was a correlation between certain prognostic factors and between some of these and a number of the blood variables.

Effect of long-term treatment with human leukocyte interferon on various laboratory parameters.

Leukocyte interferon was given by i.m. injection as adjuvant therapy to 9 patients with osteosarcoma.

Side effects of long-term treatment with human leukocyte interferon.

Twenty-nine patients, 27 of them with osteosarcoma and two with juvenile laryngeal papilloma, were followed for an aggregate period of 365 months, during which time they received long-term treatment with human leukocyte interferon. The interferon was given by intramuscular injection either daily or three times a week; the dose was 3 x 10(6) standard units. During the course of the treatment, 12 distinct symptoms were recognized as possible side effects of the drug; the three most frequent symptoms occurring after injection were fever, local pain, and shivering.

Possible tumour markers in patients with oesophagus cancer.

Carcinoembryonic antigen (CEA), alpha-foetoprotein (AFP), and enzymes were determined in the blood of 59 patients with primary oesophagus carcinoma. Raised CEA values were encountered in 59% of the patients, and AFP above that of an age-matched control group in 33% of the patients. Values of CEA during progression were significantly higher than in regression of disease.

Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparative study.

The incidence of acute infections in eight patients with osteosarcoma who are receiving interferon regularly is currently being compared with the incidence among their family members. Observations thus far indicate that the patients treated with interferon are less frequently and less severely ill than their untreated family contacts. The study is continuing, and the patients will also be observed after discontinuation of interferon treatment.